Solid-phase extraction combined with radioimmunoassay for measurement of zalcitabine (2',3'-dideoxycytidine) in plasma and serum

W. L. Roberts; T. J. Buckley; P. M. Rainey; P. I. Jatlow

doi:10.1093/clinchem/40.2.211

Solid-phase extraction combined with radioimmunoassay for measurement of zalcitabine (2',3'-dideoxycytidine) in plasma and serum

W. L. Roberts, T. J. Buckley, P. M. Rainey, P. I. Jatlow

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

Of the antiviral agents that are currently in clinical use in the US for therapy for human immunodeficiency virus infections, zalcitabine (ddC) is the most potent and is effective at the lowest plasma concentrations. The two reported procedures for measuring these low concentrations involve a chromatographic technique coupled with mass spectrometry. We have developed a procedure combining solid-phase extraction with a strong cation-exchange resin and commercially available RIA reagents for the quantification of ddC in plasma or serum. The method demonstrates good linearity, specificity, and precision, with overall CVs of

Original language	English (US)
Pages (from-to)	211-215
Number of pages	5
Journal	Clinical Chemistry
Volume	40
Issue number	2
DOIs	https://doi.org/10.1093/clinchem/40.2.211
State	Published - Jan 1 1994
Externally published	Yes

Bibliographical note

Generated from Scopus record by KAUST IRTS on 2023-09-20

ASJC Scopus subject areas

Clinical Biochemistry
Biochemistry, medical

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/clinchem/40.2.211

Cite this

@article{7efd373250cc4cf8970604aaa522aa64,

title = "Solid-phase extraction combined with radioimmunoassay for measurement of zalcitabine (2',3'-dideoxycytidine) in plasma and serum",

abstract = "Of the antiviral agents that are currently in clinical use in the US for therapy for human immunodeficiency virus infections, zalcitabine (ddC) is the most potent and is effective at the lowest plasma concentrations. The two reported procedures for measuring these low concentrations involve a chromatographic technique coupled with mass spectrometry. We have developed a procedure combining solid-phase extraction with a strong cation-exchange resin and commercially available RIA reagents for the quantification of ddC in plasma or serum. The method demonstrates good linearity, specificity, and precision, with overall CVs of",

author = "Roberts, {W. L.} and Buckley, {T. J.} and Rainey, {P. M.} and Jatlow, {P. I.}",

note = "Generated from Scopus record by KAUST IRTS on 2023-09-20",

year = "1994",

month = jan,

day = "1",

doi = "10.1093/clinchem/40.2.211",

language = "English (US)",

volume = "40",

pages = "211--215",

journal = "Clinical Chemistry",

issn = "0009-9147",

publisher = "American Association for Clinical Chemistry Inc.",

number = "2",

}

TY - JOUR

T1 - Solid-phase extraction combined with radioimmunoassay for measurement of zalcitabine (2',3'-dideoxycytidine) in plasma and serum

AU - Roberts, W. L.

AU - Buckley, T. J.

AU - Rainey, P. M.

AU - Jatlow, P. I.

N1 - Generated from Scopus record by KAUST IRTS on 2023-09-20

PY - 1994/1/1

Y1 - 1994/1/1

N2 - Of the antiviral agents that are currently in clinical use in the US for therapy for human immunodeficiency virus infections, zalcitabine (ddC) is the most potent and is effective at the lowest plasma concentrations. The two reported procedures for measuring these low concentrations involve a chromatographic technique coupled with mass spectrometry. We have developed a procedure combining solid-phase extraction with a strong cation-exchange resin and commercially available RIA reagents for the quantification of ddC in plasma or serum. The method demonstrates good linearity, specificity, and precision, with overall CVs of

AB - Of the antiviral agents that are currently in clinical use in the US for therapy for human immunodeficiency virus infections, zalcitabine (ddC) is the most potent and is effective at the lowest plasma concentrations. The two reported procedures for measuring these low concentrations involve a chromatographic technique coupled with mass spectrometry. We have developed a procedure combining solid-phase extraction with a strong cation-exchange resin and commercially available RIA reagents for the quantification of ddC in plasma or serum. The method demonstrates good linearity, specificity, and precision, with overall CVs of

UR - https://academic.oup.com/clinchem/article/40/2/211/5647938

UR - http://www.scopus.com/inward/record.url?scp=0028295413&partnerID=8YFLogxK

U2 - 10.1093/clinchem/40.2.211

DO - 10.1093/clinchem/40.2.211

M3 - Article

SN - 0009-9147

VL - 40

SP - 211

EP - 215

JO - Clinical Chemistry

JF - Clinical Chemistry

IS - 2

ER -

Solid-phase extraction combined with radioimmunoassay for measurement of zalcitabine (2',3'-dideoxycytidine) in plasma and serum

Abstract

Bibliographical note

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this